Dotinurad

Dotinurad
Clinical data
Trade names	Urece
Other names	FYU-981
Legal status
Legal status	Rx-only (Japan);
Identifiers
	IUPAC name (3,5-dichloro-4-hydroxyphenyl)-(1,1-dioxo-2H-1,3-benzothiazol-3-yl)methanone;
CAS Number	1285572-51-1;
PubChem CID	51349053;
DrugBank	DB16145;
ChemSpider	59718651;
UNII	305EB53128;
KEGG	D11071;
ChEMBL	ChEMBL4594446;
Chemical and physical data
Formula	C14H9Cl2NO4S
Molar mass	358.19 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1N(C2=CC=CC=C2S1(=O)=O)C(=O)C3=CC(=C(C(=C3)Cl)O)Cl;
	InChI InChI=1S/C14H9Cl2NO4S/c15-9-5-8(6-10(16)13(9)18)14(19)17-7-22(20,21)12-4-2-1-3-11(12)17/h1-6,18H,7H2; Key:VOFLAIHEELWYGO-UHFFFAOYSA-N;

Dotinurad (Urece) is a drug for the treatment of gout and hyperuricemia.[1][2] It was developed by Fuji Yakuhin and approved for use in Japan in 2020.[2][3] The drug is continuing clinical trials by Fortress Biotech and regulatory evaluation for approval in North America and Europe.[3][4]

Dotinurad acts as a selective urate reabsorption inhibitor that has uric acid lowering activity.[5][6]

References

Kuriyama S (March 2020). "Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia". Clinical and Experimental Nephrology. 24 (Suppl 1): 1–5. doi:10.1007/s10157-019-01811-9. PMC 7066308. PMID 31754883.
"List of Approved Products" (PDF). Pharmaceuticals and Medical Devices Agency.
"Fortress takes on dotinurad in USA and Europe". November 5, 2020. Retrieved June 23, 2021.
"Fortress Biotech Announces Exclusive License Agreement With Fuji Yakuhin to Develop Dotinurad in North America and Europe". May 10, 2021. Retrieved June 23, 2021.
Taniguchi T, Ashizawa N, Matsumoto K, Saito R, Motoki K, Sakai M, et al. (October 2019). "Pharmacological Evaluation of Dotinurad, a Selective Urate Reabsorption Inhibitor". The Journal of Pharmacology and Experimental Therapeutics. 371 (1): 162–170. doi:10.1124/jpet.119.259341. PMID 31371478. S2CID 199382932.
Uda J, Kobashi S, Miyata S, Ashizawa N, Matsumoto K, Iwanaga T (October 2020). "Discovery of Dotinurad (FYU-981), a New Phenol Derivative with Highly Potent Uric Acid Lowering Activity". ACS Medicinal Chemistry Letters. 11 (10): 2017–2023. doi:10.1021/acsmedchemlett.0c00176. PMC 7549256. PMID 33062187.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Kuriyama S (March 2020). "Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia". Clinical and Experimental Nephrology. 24 (Suppl 1): 1–5. doi:10.1007/s10157-019-01811-9. PMC 7066308. PMID 31754883.

[pmda-2] "List of Approved Products" (PDF). Pharmaceuticals and Medical Devices Agency.

[thepharmaletter-3] "Fortress takes on dotinurad in USA and Europe". November 5, 2020. Retrieved June 23, 2021.

[4] "Fortress Biotech Announces Exclusive License Agreement With Fuji Yakuhin to Develop Dotinurad in North America and Europe". May 10, 2021. Retrieved June 23, 2021.

[5] Taniguchi T, Ashizawa N, Matsumoto K, Saito R, Motoki K, Sakai M, et al. (October 2019). "Pharmacological Evaluation of Dotinurad, a Selective Urate Reabsorption Inhibitor". The Journal of Pharmacology and Experimental Therapeutics. 371 (1): 162–170. doi:10.1124/jpet.119.259341. PMID 31371478. S2CID 199382932.

[6] Uda J, Kobashi S, Miyata S, Ashizawa N, Matsumoto K, Iwanaga T (October 2020). "Discovery of Dotinurad (FYU-981), a New Phenol Derivative with Highly Potent Uric Acid Lowering Activity". ACS Medicinal Chemistry Letters. 11 (10): 2017–2023. doi:10.1021/acsmedchemlett.0c00176. PMC 7549256. PMID 33062187.